Stem Cell Therapy

What Is Ryoncil?

What Ryoncil is, who it is approved for, how it is given, and clinic differences.

Ryoncil is an allogeneic bone marrow-derived mesenchymal stromal cell therapy approved by the Food and Drug Administration on December 18, 2024. It is approved for pediatric patients 2 months of age and older who have steroid-refractory acute graft-versus-host disease.

Hospital transplant teams give it by intravenous infusion.

What Ryoncil Is

Ryoncil (remestemcel-L-rknd) is an FDA-approved allogeneic bone marrow-derived mesenchymal stromal cell therapy, approved December 18, 2024 for children 2 months and older with steroid-refractory acute graft-versus-host disease. Mesoblast manufactures it, and it is a hospital-administered biologic. It is not an outpatient wellness injection.

The Food and Drug Administration (FDA) approved Ryoncil as the first mesenchymal stromal cell (MSC) therapy approved in the United States. The approval carried fast track, orphan drug, and priority review designations. The biologic is allogeneic, meaning the cells come from a donor, not the patient.

Ryoncil is not a gene therapy and it is not a chimeric antigen receptor T-cell (CAR-T) product. Our mesenchymal stem cells guide explains the cell type.

Approved Patient Population

The FDA approved Ryoncil exclusively for pediatric patients 2 months of age and older with steroid-refractory acute graft-versus-host disease (SR-aGVHD).

In the approval trial, SR-aGVHD was defined as disease progression within 3 days, or a lack of improvement within 7 consecutive days, of methylprednisolone dosed at 2 milligrams per kilogram per day or equivalent. Eligible participants had Grade B to Grade D acute graft-versus-host disease under the International Bone Marrow Transplant Registry (IBMTR) Severity Index. The protocol excluded patients whose only manifestation was Grade B skin involvement, as well as patients who had already received second-line aGVHD therapy before screening.

This approval does not extend to adult patients.

Administration and Dosing Schedule

Ryoncil is given as an intravenous infusion in a hospital transplant setting. The standard dosing protocol requires 2 million mesenchymal stromal cells per kilogram of the patient’s body weight per infusion. The care team administers these infusions twice a week for 4 consecutive weeks, 8 infusions in total, spaced at least 3 days apart.

Treatment may continue based on response at 28 days after the initial dose.

Storage and handling information appears on the prescribing label. Read the current FDA approval announcement and ask the transplant team for the prescribing label.

Approval Trial Findings

The FDA approval rests on study MSB-GVHD001 (NCT02336230). This prospective, multicenter, single-arm clinical trial evaluated Ryoncil in 54 pediatric patients who developed SR-aGVHD following an allogeneic hematopoietic stem cell transplant.

Because the study utilized a single-arm design, investigators did not compare Ryoncil against a concurrent placebo or active control arm. The trial reported the overall response rate (ORR) at Day 28. The overall response rate reached 70 percent (95 percent confidence interval, 56.4 to 82.0 percent).

Among individual response categories, 30 percent of trial participants attained a complete response (95 percent confidence interval, 18.0 to 43.6 percent). A partial response occurred in 41 percent of patients (95 percent confidence interval, 27.6 to 55.0 percent). Across all responding patients, the median duration of response was 54 days, with individual durations ranging from 7 days to more than 159 days.

Reported Adverse Reactions

The most common nonlaboratory adverse reactions (incidence 20 percent or higher) were:

  • Viral infectious disorders
  • Bacterial infectious disorders
  • Infection with pathogen unspecified
  • Pyrexia (fever)
  • Hemorrhage
  • Edema
  • Abdominal pain
  • Hypertension

Full warnings and contraindications are in the prescribing label from the transplant team.

Serious adverse events can be reported to FDA MedWatch or by calling 1-800-FDA-1088. Our safety and side effects guide covers the risks of clinic injections.

Ryoncil vs Clinic Stem Cell Injections

Ryoncil is an FDA-approved drug for pediatric SR-aGVHD. Clinics offering stem cell injections for knee arthritis, back pain, wellness or anti-aging are not selling Ryoncil.

AttributeRyoncil (remestemcel-L-rknd)Outpatient Clinic Injections
Regulatory StatusFDA approved (December 18, 2024)No MSC product FDA approved for those uses
Delivery SettingHospital transplant settingClinic
Published Price$194,000 per infusion (list price)Varies by clinic
Approved IndicationPediatric SR-aGVHD onlyNone for knee arthritis, back pain, wellness or anti-aging

No MSC product is FDA approved for knee arthritis, back pain, wellness or anti-aging. Patients evaluating marketing claims can learn how to scrutinize sales pitches in our guide on how to vet a clinic.

Adult Access and the Phase 3 Trial

Adults are not an approved population for Ryoncil.

Mesoblast is running an adult trial with the National Institutes of Health (NIH) funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN). A registration-directed Phase 3 trial in adult patients with steroid-refractory acute graft-versus-host disease initiated enrollment during Mesoblast’s fiscal year 2026. The trial is enrolling at multiple U.S. sites.

No readout date or filing timeline for adults has been published. Adults are not an approved population.

Pricing and Insurance Coverage

Mesoblast set a list price of $194,000 per infusion.

Aetna Clinical Policy Bulletin 1077 covers Ryoncil only for pediatric SR-aGVHD. The bulletin treats other uses as experimental, investigational, or unproven. More on cost is in our dedicated Ryoncil cost analysis.

Questions for the Care Team

Questions to ask the transplant team:

  • Does the patient’s disease grade and steroid response meet the SR-aGVHD definition used in the approval trial?
  • What specific infection prophylaxis and surveillance protocols will the team deploy during the 8-infusion schedule?
  • What measurable changes at the Day 28 evaluation will decide whether infusions should continue or stop?
  • Has the hospital’s financial navigation office submitted prior authorization under policy guidelines like Aetna Bulletin 1077?
  • Who on the care team reports adverse events to FDA MedWatch?

Our FDA status guide explains how to check what a product is approved for before you evaluate any cell therapy proposal.

Frequently asked questions

What is Ryoncil?

Ryoncil is the brand name of remestemcel-L-rknd, an allogeneic bone marrow-derived mesenchymal stromal cell product manufactured by Mesoblast. The Food and Drug Administration approved it on December 18, 2024, making it the first approved mesenchymal therapy in the United States.

Is Ryoncil FDA approved?

Yes. The Food and Drug Administration approved Ryoncil on December 18, 2024, under fast track, priority review, and orphan drug designations. The approval covers children 2 months of age and older who have steroid-refractory acute graft-versus-host disease.

Is Ryoncil a gene therapy or CAR-T?

No. Ryoncil is not a gene therapy and it is not a chimeric antigen receptor T-cell therapy. It is a donor mesenchymal stromal cell product derived from bone marrow.

How is Ryoncil given?

Ryoncil is administered as an intravenous infusion at a dose of 2 million mesenchymal stromal cells per kilogram of body weight. Patients receive two infusions per week for 4 consecutive weeks, totaling 8 infusions spaced at least 3 days apart. Whether treatment continues depends on response at 28 days after the first dose.

What are the side effects of Ryoncil?

The most common nonlaboratory adverse reactions occurring in 20 percent or more of clinical trial patients include viral infections, bacterial infections, infections with unspecified pathogens, fever, hemorrhage, edema, abdominal pain, and high blood pressure. Adverse reactions can be reported to FDA MedWatch.

Can adults get Ryoncil?

No. Adults are not an approved population for Ryoncil. A Phase 3 clinical trial for adults with steroid-refractory acute graft-versus-host disease began during Mesoblast's fiscal year 2026 with the Blood and Marrow Transplant Clinical Trials Network, but no readout date or filing timeline is published.

Medical disclaimer. Medical Frontier is an independent educational resource. This page is for general information only and is not medical advice, diagnosis, or treatment, and does not create a doctor–patient relationship. Most regenerative therapies discussed here are not FDA-approved for the uses described and may be offered under limited exemptions or in clinical trials only. Always consult a licensed physician before making any treatment decision.